The Anti-Spasm formula provides comforting support to the gastrointestinal tract, using herbs noted for their anti-spasmodic and carminative (gas-relieving) effects.
In addition to premium quality peppermint oil, this innovative formula features the added benefits of English lavender oil and chamomile, herbs well known for their relaxing and stress relieving properties.
Anti-Spasm Support has an enteric coating that allows targeted delivery of the oils to the lower intestine for maximum effectiveness.
Product Info
Beyond their comforting effects, peppermint and lavender are also active against unfriendly bacteria and yeast, which can strongly contribute to intestinal dysfunction.
Anti-Spasm Support may be of interest to people who suffer digestive discomforts such as cramps, gas, and bloating, and even people without discomfort who simply wish to improve their digestive health.
If pregnant or nursing, or taking medication, consult your healthcare practitioner before use.
Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L.
Section of Digestive Sciences, Department of Medicine, G d'Annunzio University, Chieti-Pescara, Italy.
INTRODUCTION: The use of peppermint oil in treating the irritable bowel syndrome has been studied with variable results probably due to the presence of patients affected by small intestinal bacterial overgrowth, lactose intolerance or celiac disease that may have symptoms similar to irritable bowel syndrome. AIM: The aim of the study was to test the effectiveness of enteric-coated peppermint oil in patients with irritable bowel syndrome in whom small intestinal bacterial overgrowth, lactose intolerance and celiac disease were excluded. METHODS: Fifty-seven patients with irritable bowel syndrome according to the Rome II criteria, with normal lactose and lactulose breath tests and negative antibody screening for celiac disease, were treated with peppermint oil (two enteric-coated capsules twice per day or placebo) for 4 weeks in a double blind study. The symptoms were assessed before therapy (T(0)), after the first 4 weeks of therapy (T(4)) and 4 weeks after the end of therapy (T(8)). The symptoms evaluated were: abdominal bloating, abdominal pain or discomfort, diarrhoea, constipation, feeling of incomplete evacuation, pain at defecation, passage of gas or mucus and urgency at defecation. For each symptom intensity and frequency from 0 to 4 were scored. The total irritable bowel syndrome symptoms score was also calculated as the mean value of the sum of the average of the intensity and frequency scores of each symptom. RESULTS: At T(4), 75% of the patients in the peppermint oil group showed a >50% reduction of basal (T(0)) total irritable bowel syndrome symptoms score compared with 38% in the placebo group (P<0.009). With peppermint oil at T(4) and at T(8) compared with T(0) a statistically significant reduction of the total irritable bowel syndrome symptoms score was found (T(0): 2.19+/-0.13, T(4): 1.07+/-0.10*, T(8): 1.60+/-0.10*, *P<0.01 compared with T(0), mean+/-S.E.M.), while no change was found with the placebo. CONCLUSION: A 4 weeks treatment with peppermint oil improves abdominal symptoms in patients with irritable bowel syndrome.
More Reading material ... J Gastroenterol. 1997 Dec;32(6):765-8.Links
Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial.Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK.
Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan.
To determine the efficacy and tolerability of an enteric-coated peppermint-oil formulation (Colpermin), we conducted a prospective, randomized, double-blind, placebo-controlled clinical study in 110 outpatients (66 men/44 women; 18-70 years of age) with symptoms of irritable bowel syndrome. Patients took one capsule (Colpermin or placebo) three to four times daily, 15-30 min before meals, for 1 month. Fifty-two patients on Colpermin and 49 on placebo completed the study. Forty-one patients on Colpermin (79%) experienced an alleviation of the severity of abdominal pain (29 were pain-free); 43 (83%) had less abdominal distension, 43 (83%) had reduced stool frequency, 38 (73%) had fewer borborygmi, and 41 (79%) less flatulence. Corresponding figures for the placebo group were: 21 patients (43%) with reduced pain (4 were pain-free), 14 (29%) with reduced distension, 16 (32%) with reduced stool frequency, 15 (31%) with fewer borborygmi, and 11 (22%) with less flatulence. Symptom improvements after Colpermin were significantly better than after placebo (P < 0.05; Mann-Whitney U-test). One patient on Colpermin experienced heartburn (because of chewing the capsules) and one developed a mild transient skin rash. There were no significant changes in liver function test results. Thus, in this trial, Colpermin was effective and well tolerated.
Label
Directions: Take one softgel three times daily before meals or as directed by your healthcare provider.
Other Ingredients: Gelatin, rice bran oil, glycerin silica, and enteric coating.
Suitable for vegetarians if removed from softgel.
♦ These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.
